This inventor holds 3 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 2 EPO patents. Top assignee: Chong Kun Dang Pharmaceutical Corporation. Active years: 2024-2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2024-2026
Title: Inventor Spotlight: Hokeun Yun and His Groundbreaking Patent
Introduction: Hokeun Yun, a notable inventor residing in Gyeonggi-do, South Korea, has made significant contributions to the field of pharmaceuticals. With a focus on innovative compounds, he seeks to address critical health issues through his research and invention. His work in developing novel histone deacetylase 6 (HDAC6) inhibitors has the potential to impact various diseases.
Latest Patents: Hokeun Yun holds a patent for the invention titled "1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same." This patent encompasses new compounds that exhibit HDAC6 inhibitory activity, alongside their optical isomers and pharmaceutically acceptable salts. These compounds showcase promise in the prevention and treatment of a range of HDAC6-related diseases, including infectious diseases, neoplasms, metabolic disorders, and various neurological and circulatory conditions.
Career Highlights: Hokeun Yun is associated with Chong Kun Dang Pharmaceutical Corporation, where he has contributed to advancing pharmaceutical research. His innovative spirit and dedication to addressing complex health problems underscore his role in the industry. The patent he holds serves as a testament to his commitment to developing effective pharmaceutical solutions.
Collaborations: Throughout his career, Hokeun has worked alongside esteemed colleagues, including Chang Sik Lee and Jung Taek Oh. Their collective efforts in research and development have fostered an environment of innovation, leading to impactful discoveries in the pharmaceutical sector.
Conclusion: Hokeun Yun's contributions through his patent reflect a significant advancement in the search for effective treatments related to HDAC6-related diseases. His work at Chong Kun Dang Pharmaceutical Corporation, alongside talented collaborators, positions him as a noteworthy figure in the realm of pharmaceutical innovation. The potential applications of his compounds could pave the way for improved therapeutic options in various medical fields.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile